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Cytomegalovirus (CMV) infection remains a major cause of
morbidity and mortality in renal transplant recipients, and may
be associated with reduced graft survival U, 21. Restriction
enzyme analysis of CMV isolates [3—5) has clearly established
that the donor kidney may be the source of CMV contamina-
tion, especially in CMV seronegative recipients who are at high
risk for serious CMV disease [6]. This study, based on gene
amplification by the polymerase chain reaction (PCR) [7], was
undertaken to determine the incidence of CMV genome in
kidneys from 30 patients. PCR has been successfully applied to
the identification of CMV genome in urine, blood and saliva
[8—13]. Since for ethical reasons we were reluctant to perform
donor kidney biopsies in this initial study, we selected samples
from patients undergoing a kidney biopsy justified by renal
disease symptoms or a nephrectomy for cancer. The results
show that kidneys from 8 of 20 seropositive patients contained
CMV genetic material by Southern blot analysis. Unexpect-
edly, the latter could also be detected in 3 of 10 seronegative
patients.
Methods
Patients
CMV genome was searched for in kidney biopsies taken from
27 consecutive patients referred for symptoms of renal disease
(proteinuria, hematuria, and/or renal insufficiency) and in three
additional specimens from the "normal" pole of kidneys with
cancer. None of the patients showed clinical signs of CMV
infection; only one with endocarditis had persistent fever.
Biopsies were processed as previously described for light
microscopy and immunofluorescence studies [14]. Histological
diagnoses are given in Table 1.
Serological studies
The serologic status of the patients was established using the
CMV latex agglutination assay (CMV Scan®, Becton Dickin-
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son) [15] and an enzyme immunoassay (ELISA) set up in our
laboratory. Antigen was prepared from MRC-5 cells infected by
CMV and showing >90% cytopathic effects. A control prepa-
ration was made from uninfected cells treated in parallel.
Ninety-six-well NUNC plates were coated with 2.5 g antigen!
well/0.l ml of PBS, saturated with 1% BSA and successively
incubated with sera diluted 1/100 in PBS containing 0.1%
Tween 20 (PBS-T), peroxidase-labeled sheep anti-human IgG
(Diagnostics Pasteur) and substrate (OPD). Each incubation
step was followed by washes in PBS-T. Results are expressed
as delta OD (average OD of two wells coated with infected cell
antigen-average OD of two wells coated with uninfected cell
antigen). A delta OD of 0.2 was considered negative.
Detection of CMV genome by PCR amplification
Processing of samples. Renal biopsy fragments were ground
mechanically and incubated for 48 hours at 37°C in 500 p1 of
lysis buffer (0.1 M Tris, pH 7.4, 0.01 M EDTA, 0.5% SDS)
containing 200 g/ml of Proteinase K (Merck). Samples were
then extracted twice with a phenol (vol/vol 50%)-chloroform
(48%)-isoamyl alcohol (2%) mixture. DNA was precipitated
with ethanol and resuspended in 20 .d of distilled water.
Amplification procedure. The primers used for specific am-
plification of CMV DNA (A, 5'-GGA TCC GCA TGG CAT
TAC CGT ATG T-3' and D, 5'-GAA TTC AGT GGA TAA CCT
GCG GCG A-3') were synthesized (Laboratoire de Chimie
Organique, Institut Pasteur, France) based on sequence data of
Weston and Barrell [16]. They frame a 406 bp region within the
HindIII-X fragment of the Ad- 169 CMV strain which region was
found to be highly conserved in 60 fresh human isolates of CMV
examined (unpublished results and Fig. 1). Each DNA speci-
men was amplified for 30 cycles using a Hybaid apparatus (Cera
Labo) in two independent double-blind experiments. Briefly, 3
.d of DNA solution were first diluted to a final volume of 20 p1
in distilled water and boiled for 30 minutes. The reaction
mixture (100 Ld) consisted of 15 p1 of each deoxyribonucleotide
(stock solution: 10 mM); 6 p1 of 0.6 M Tris, pH 8.8, 0.17 M
ammonium sulfate, 67 mivi MgCl2, 0.1 M /3-mercaptoethanol, 50
/iM EDTA, 1.7 mg!ml bovine serum albumin; 10 p1 dimethyl-
sulfoxide; 1 p1 of each primer (stock solution: 1 mM); and 3 p1
(1.5 U) of Taql polymerase (Perkin-Elmer). After five minutes
of annealing at 55°C, elongation was carried out at 70°C for five
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Table 1. Characteristics of patients and CMV status
Hybridization of PCR
Patient
number Age Sex Lesionsa
Serology productsb
Dot dig SouthernScan ELISA
1 67 M Cancer + + + +
2 48 F Amyl. + + — +
3 64 F Memb.GN + + + +
4 60 M En.Ex.GN (Endoc.) + — + +
5 70 M Granul.TIN + + — +
6 63 M Fibrosis + + — +
7 66 F MPGN (Cryo.) + + — +
8 54 M FSG + + — —
9 57 F FSGN (IgA) + ND — +
10 23 M Minimal + + + —
11 34 M FSG + + — —
12 35 M En.Ex.GN (IgA) + + —
13 63 M Amyl. + ND —
14 48 M Ex.Nec.GN + + — —
15 54 M FSG (Diab.) + + — —
16 78 M Ex.Nec.GN + + —
17 42 M Goodpasture + + — —
18 49 F Fibrosis — + — —
19 66 M Memb.GN + ND - -
20 68 F Tub.Necr. — + — —
21 18 M Post-inf.GN — —
22 67 M Cancer — —
23 72 M Ex.Nec.GN — —
24 23 M Uncl.GN — — — —
25 17 F Mes.GN (Lupus) — — — —
26 51 M Memb.GN - - -
27 16 M Min.change — — +
28 54 M Cancer — — + +
29 22 M Ex.GN (IgA) — — + +
30 18 M En.GN (IgA) — ND + +
a Abbreviations are: Amyl., amyloidosis; Cryo., cryoglobulinemia; Diab., diabetes; En. Ex., endo- and extra-capillary; Endoc., endocarditis;
Ex. Nec., extra-capillary and necrotizing; FSG, focal and segmental glomerulosclerosis; GN, glomerulonephritis; Granul. TIN, granulomatous
tubulointerstitial nephritis; Memb., membranous; Mes., mesangiocapillary; Mm., minimal; MPGN, membranoproliferative; Post-inf., post-
infectious; Tub. Necr., tubular necrosis; Unci., unclassified; N.D., not done because of serum shortage.b Following 30 cycles of amplification, PCR products were hybridized with an insert from plasmid pPR containing a 208bp sequence framed by
the primers. Dot-blot hybridization was detected using this probe labeled with digoxygenin (Dot dig).
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Fig. 1. Hind III restriction map of Ad-169 CMV strain according to
Fleckenstein et a! [22] and Oram et a! [23]. The 406 bp region that we
amplified is delineated by a BamHI (B) and an EcoRI (E) restriction
site. These restriction sites are conserved among 60 wild CMV isolates.
The probe pPR (*), delimited by two Sau3AI (S) sites, was cloned in a
pGEM vector.
minutes. Samples were subsequently cycled as follows: dena-
turation, 10 seconds at 94°C; annealing, one minute at 55°C and
elongation, one minute at 70°C.
Amplification products were transferred to nitrocellulose by
dot-blotting and hybridized with a specific probe. They were
also analyzed by electrophoresis in 2% agarose gels followed by
ethidium bromide staining. Blots were made of the same gels
according to the Suothern technique [17].
Specificity of amplification was controlled using cellular
DNA as well as DNA purified from other human Herpes viruses
(Herpes Simplex virus types 1 and 2, Varicella-Zoster virus,
Epstein-Barr virus, Human herpes virus 6) and Colburn Simian
virus. Controls also consisted of DNA samples prepared from
30 mice kidneys which were amplified in parallel with the
human renal biopsies. Each reaction contained a positive viral
DNA and a negative water control. All amplifications were
performed twice independently.
Hybridization of filters. Hybridization was performed with
the gel purified plasmid pPR, a Sau3Al subfragment of the
HindIII-X fragment. The probe was labeled with either alpha
32PdCTP (Southern blots) by nick translation or with digoxy-
genin tagged-deoxyuridine triphosphate (dig-dUTP) by random
priming (pPR-dig) using a kit purchased from Boehringer-
Mannheim (dot blots). Filters were hybridized overnight at 68°C
and washed under stringent conditions in sequential baths of 2
x SSC, 0.1% SDS, then 1 x SSC, 0.1% SDS, and finally 0.1 x
SSC, 0.1% SDS, as previously described [18]. Dot blots were
developed according to the manufacturer's instruction, and
results were scored "+" or "—" after drying of the blots.
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Fig. 2. Southern blot hybridization of PCR
products with a speqflc CMV probe. After
amplification in parallel of mouse kidney DNA
and human renal biopsy DNA, PCR products
were separated by electrophoresis and
transferred to nitrocellulose according to the
Southern technique 117]. Blots were
hybridized with a subfragment of the Hind
III-X fragment. Numbers for human biopsies
correspond to the numbers in Table 1.
Arrowheads indicate hybridization with the
specific 406 bp amplification product. A
negative (—) and a positive (+) control were
amplified in parallel.
Results and discussion although a small number of samples (patients 3, 18 and 20) gave
discordant results with the two tests. By Southern blot (Fig. 2),
Detection of CMV genome in seropositive patients 8 of the 20 kidney specimens yielded a 406 bp band character-
Twenty patients of this series had anti-CMV antibodies by istic of the PCR amplification product of the CMV genome.
the latex agglutination assay and/or EIA (Table 1). They in- Only 3 of them showed clear positivity by dot blot with a
eluded 14 males and 6 females aged from 23 to 78 years (mean nonradioactive labeled probe. Although this technique can be
age 59). The sensitivity of the latex agglutination was similar to more widely used in hospital-associated laboratories, its inter-
that of the enzyme immunoassay developed in our laboratory, est was limited in our hand by its lower sensitivity. It may also
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lead to false-positive results, as in patient 9 in whom the
positive dot blot could not be confirmed by a detectable band on
the Southern blot.
These results suggest that the CMV genome may persist in
the kidney after serologically-proven viral infection, and most
likely explain why kidneys from seropositive individuals may
be a source of contamination upon grafting.
Detection of CMV genome in seronegative patients
This group was composed of nine males and one female
ranging in age from 16 to 72 years (mean age 36; Table 1). All
were negative by both serological tests. CMV DNA could be
found in 3 of 10 patients (Fig. 2), who were positive by both dot
and Southern blots, while one was only positive by dot blot. All
samples of mouse kidney amplified in parallel were negative.
These results confirm the high sensitivity of PCR methods.
They are in keeping with previous observations made in trans-
planted patients. First, in renal transplant recipients, PCR assay
was shown to be the most sensitive test to detect CMV in urines
when compared with enzyme-linked immunosorbent assay,
DNA hybridization and direct virus isolation [121. This finding
was recently confirmed by LOning et al [19] who demonstrated
CMV DNA by PCR despite negativity of in situ hybridization
and immunohistochemistry. Second, in bone marrow grafted
patients, a prospective longitudinal study indicated that CMV
DNA detection by PCR in blood was more sensitive than virus
culture and CMV antibody status for the diagnosis of CMV
infection [10]. Moreover, epidemiological studies have shown
that seronegative subjects may be positive for CMV genome by
PCR [20]. Our data further suggest that kidneys from seroneg-
ative donors may also be contaminating, although further study
is required to establish correlation between PCR positivity and
infectious potential.
It is interesting to note that in the two groups of patients
taken as a whole, serologic and PCR data did not correlate with
any type of nephropathy.
In conclusion, the present study shows the feasibility of PCR
assay for the specific detection of CMV genome in kidney
biopsies. This test may be a powerful tool to study in more
detail the transmission of CMV infection in kidney recipients
and to analyze the relationship between CMV infection and
graft rejection. Furthermore, it indicates that, because of the
high incidence (37%) of CMV genome in kidney biopsies, one
must be very cautious when interpreting the possible relation-
ship between its detection and the pathogenesis of certain types
of glomerulonephritis recently suggested by Muller et al for IgA
nephropathy [21].
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